Table 1.
Patient characteristics and treatment/management options of 1088 patients with prostate cancer who were diagnosed between January 2005 and December 2013
| All (N = 1088) |
RP (n = 661) |
RT (n = 181) |
ADT (n = 105) |
AS (n = 141) |
P-value | |
|---|---|---|---|---|---|---|
| n (row %) | ||||||
| Age (y) | <.0001 | |||||
| ≤60 | 445 | 365 (82.0) | 32 (7.2) | 19 (4.3) | 29 (6.5) | |
| >60 to ≤70 | 457 | 270 (59.1) | 81 (17.7) | 38 (8.3) | 68 (14.9) | |
| > 70 | 186 | 26 (14.0) | 68 (36.6) | 48 (25.8) | 44 (23.7) | |
| Race/ethnicity | <.0001 | |||||
| White | 453 | 364 (80.4) | 32 (7.1) | 13 (2.9) | 44 (9.7) | |
| Black | 420 | 176 (41.9) | 110 (26.2) | 63 (15.0) | 71 (16.9) | |
| Hispanic/Latino | 130 | 78 (60.0) | 23 (17.7) | 19 (14.6) | 10 (7.7) | |
| Other | 85 | 43 (50.6) | 16 (18.8) | 10 (11.8) | 16 (18.8) | |
| Primary language | <.0001 | |||||
| English | 847 | 550 (64.9) | 129 (15.2) | 70 (8.3) | 98 (11.6) | |
| Spanish | 101 | 60 (59.4) | 18 (17.8) | 15 (14.9) | 8 (7.9) | |
| Haitian Creole | 71 | 21 (29.6) | 18 (25.4) | 12 (16.9) | 20 (28.2) | |
| Other | 69 | 30 (43.5) | 16 (23.2) | 8 (11.6) | 15 (21.7) | |
| Insurance status | <.0001 | |||||
| Commercial/Private | 403 | 317 (78.7) | 33 (8.2) | 16 (4.0) | 37 (9.2) | |
| Medicaid/Free care | 278 | 161 (57.9) | 46 (16.6) | 32 (11.5) | 39 (14.0) | |
| Medicare/Military | 407 | 183 (45.0) | 102 (25.1) | 57 (14.0) | 65 (16.0) | |
| Marital status | <.0001 | |||||
| Married | 643 | 434 (67.5) | 80 (12.4) | 49 (7.6) | 80 (12.4) | |
| Single | 284 | 152 (53.5) | 59 (20.8) | 34 (12.0) | 39 (13.7) | |
| Other | 161 | 75 (46.6) | 42 (26.1) | 22 (13.7) | 22 (13.7) | |
| AJCC | <.0001 | |||||
| Stage II | 985 | 586 (59.5) | 170 (17.3) | 88 (8.9) | 141 (14.3) | |
| Stage III | 103 | 75 (72.8) | 11 (10.7) | 17 (16.5) | 0 (0.0) | |
| Risk category | <.0001 | |||||
| Low | 503 | 344 (68.4) | 52 (10.3) | 1 (0.20) | 106 (21.1) | |
| Intermediate | 411 | 276 (67.2) | 83 (20.2) | 25 (6.1) | 27 (6.6) | |
| High | 174 | 41 (23.6) | 46 (26.4) | 79 (45.4) | 8 (4.6) | |
ADT, androgen deprivation therapy; AJCC, American Joint Committee on Cancer; AS, active surveillance; RP, radical prostatectomy; RT, radiation therapy.